相似文献
1
Phase II study of 5-fluorouracil (5-FU) and high dose folinic acid (HDFA) in hepatocellular carcinoma.5-氟尿嘧啶（5-FU）与高剂量亚叶酸（HDFA）用于肝细胞癌的II期研究。
Br J Cancer. 1988 Mar;57(3):319. doi: 10.1038/bjc.1988.71.
2
Mitoxantrone, 5-FU + folinic acid, mitomycin C for regional chemotherapy of malignant liver tumors.米托蒽醌、5-氟尿嘧啶+亚叶酸钙、丝裂霉素C用于恶性肝肿瘤的区域化疗。
Gan To Kagaku Ryoho. 1996 Sep;23(11):1380.
3
Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study.聚乙二醇化脂质体阿霉素、5-氟尿嘧啶和亚叶酸钙在不可切除肝细胞癌中的活性与安全性：一项II期研究
World J Gastroenterol. 2007 Dec 28;13(48):6553-7. doi: 10.3748/wjg.v13.i48.6553.
4
Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.接受肝动脉灌注化疗的晚期肝细胞癌患者的预后因素
J Gastroenterol. 2005 Jan;40(1):70-8. doi: 10.1007/s00535-004-1494-7.
5
Intraarterial chemotherapy: another choice for unresectable advanced hepatocellular carcinoma?
J Chin Med Assoc. 2004 Dec;67(12):595-6.
6
Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis.索拉非尼联合奥沙利铂、5-氟尿嘧啶和亚叶酸钙经肝动脉灌注同步治疗伴有主要门静脉血栓形成的不可切除肝细胞癌的II期研究
Cardiovasc Intervent Radiol. 2018 May;41(5):734-743. doi: 10.1007/s00270-017-1874-z. Epub 2018 Jan 11.
7
Phase II intravenous study of epirubicin with 5-fluorouracil in patients with advanced hepatocellular carcinoma.表柔比星联合5-氟尿嘧啶用于晚期肝细胞癌患者的II期静脉内研究。
Eur J Cancer. 1991;27(12):1620-2. doi: 10.1016/0277-5379(91)90428-g.
8
Fibrolamellar hepatocellular carcinoma responsive to platinum-based combination chemotherapy.
Clin Oncol (R Coll Radiol). 1996;8(5):331-3. doi: 10.1016/s0936-6555(05)80724-1.
9
Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study.氟尿嘧啶联合高剂量的亚叶酸纯（6S）立体异构体治疗晚期结直肠癌患者：一项I-II期研究。
J Natl Cancer Inst. 1992 Mar 4;84(5):321-7. doi: 10.1093/jnci/84.5.321.
10
Systemic cytostatic drug therapy in liver cancer.肝癌的全身细胞毒性药物治疗。
Ann Chir Gynaecol Suppl. 1986;200:69-73.
引用本文的文献
1
Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma.改良的顺铂/干扰素 α-2b/多柔比星/5-氟尿嘧啶（PIAF）化疗在无肝炎或肝硬化的患者中与提高初始不可切除肝癌的反应率、可切除性和生存率相关。
Cancer. 2013 Sep 15;119(18):3334-42. doi: 10.1002/cncr.28209. Epub 2013 Jul 2.
2
Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma.静脉持续输注氟尿嘧啶联合聚乙二醇干扰素α-2a 皮下注射治疗晚期肝细胞癌。
J Gastroenterol. 2012 Oct;47(10):1152-9. doi: 10.1007/s00535-012-0574-3. Epub 2012 Mar 22.
3
Hepatocellular carcinoma.肝细胞癌
Postgrad Med J. 2000 Jan;76(891):4-11. doi: 10.1136/pmj.76.891.4.
4
In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines.
Cancer Chemother Pharmacol. 1992;30(6):417-22. doi: 10.1007/BF00685591.
本文引用的文献
1
Reporting results of cancer treatment.癌症治疗结果报告。
Cancer. 1981 Jan 1;47(1):207-14. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6.
2
Primary hepatocellular cancer--present results and future prospects.原发性肝细胞癌——当前结果与未来前景。
Int J Radiat Oncol Biol Phys. 1983 Dec;9(12):1841-50. doi: 10.1016/0360-3016(83)90352-8.
3
Selective modulation of 5-fluorouracil action in patients with colorectal carcinoma.
Chemioterapia. 1985 Oct;4(5):377-82.
4
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.用5-氟尿嘧啶和高剂量亚叶酸治疗晚期结直肠癌和胃腺癌。
J Clin Oncol. 1986 May;4(5):685-96. doi: 10.1200/JCO.1986.4.5.685.
5
Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients.阿霉素治疗肝细胞癌。109例患者的经验。
Cancer. 1985 Dec 15;56(12):2751-5. doi: 10.1002/1097-0142(19851215)56:12<2751::aid-cncr2820561205>3.0.co;2-o.
6
Two-stage plans for patient accrual in phase II cancer clinical trials.II期癌症临床试验中患者入组的两阶段计划。
Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1721-6.
Zotero 插件